FOLH1 and prostate cancer: More recently, generator produced 44Sc was used for the first in-human PET imaging of patients with metastasised castration resistant prostate cancer via radiolabelling a prostate-specific membrane antigen (PSMA) targeting ligand (Vipivotide tetraxetan—PSMA-617) (Eppard et al. 2017).